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The patient described above has moderate 
to severe ovarian hyperstimulation syn-
drome (OHSS), the most serious maternal 
complication of gonadotropin therapy. 
OHSS poses a significant risk of maternal 
morbidity and mortality as well as preg-
nancy loss. The patient’s risk factors for 
having OHSS include youth, excessive 
ovarian stimulation, PCOS, and a likely 
twin gestation. Signs and symptoms of 
severe OHSS include abdominal disten-
tion, compromised renal function (includ-
ing renal failure) due to decreased renal 
perfusion secondary to pressure from 
tense ascites and decreased intravascular 
volume, respiratory compromise due to 
pleural effusion and pulmonary edema, 
thromboembolism (including stroke) due 
to hemoconcentration and high estrogen 
levels, ovarian rupture, electrolyte abnor-
malities, and liver dysfunction. Although 
most cases are mild and self limited, 
severe cases can result in acute respira-
tory distress syndrome (ARDS) or stroke 
and can require intensive care unit (ICU) 
admission to prevent death.
Current knowledge
Older literature suggests that significant 
ovarian hyperstimulation occurs in excess 
of 3% of gonadotropin stimulation cycles, 
but more recent data suggest a rate of less 
than 1% per cycle (1). The reduction in 
OHSS cases likely reflects better recogni-
tion of risk factors and multiple improve-
ments in infertility therapy, mitigating the 
need for overly aggressive ovarian stimu-
lation and increasing the ability to assess 
risk. However, OHSS is not completely 
preventable or predictable (2). Further-
more, the continued expansion in IVF uti-
lization worldwide and in the US increases 
the public health importance of strategies 
to prevent and treat OHSS (3).
While the cause of OHSS is not com-
pletely understood, it clearly involves 
an exaggerated response to iatrogenic 
gonadotropin therapy (except in very rare 
cases). The development of moderate to 
severe symptoms is completely depen-
dent on ovarian enlargement in addi-
tion to the elaboration of factors, such 
as VEGF, by the corpora lutea that cause 
capillary leakage. Stimulation of the cor-
pora lutea by high levels of endogenous or 
exogenous hCG or luteinizing hormone 
(LH) exacerbates the problem by increas-
ing the secretion of corpora lutea factors 
and maintaining ovarian size.
Because the development of severe 
OHSS is absolutely dependent on LH 
receptor stimulation by endogenous or 
exogenous LH or hCG, many strategies 
have been employed to limit the magni-
tude and duration of stimulation. Some 
strategies, such as the use of progesterone 
instead of hCG for luteal support or reduc-
ing the gonadotropin dose for patients 
with a high risk of OHSS, have been wide-
ly accepted because they do not adversely 
affect pregnancy rates (4). Other strate-
gies, including the use of gonadotropin-
releasing hormone (GnRH) agonists to 
trigger endogenous LH, are associated 
with a lower pregnancy rate and, thus, 
have not been as readily adopted (5). 
Although in vitro maturation of oocytes 
holds the promise to eliminate or limit the 
need for ovarian stimulation altogether, 
technical hurdles and relatively low effica-
cy of current oocyte maturation technolo-
gies greatly limit its use.
Research advance
In this issue, Jayasena and Abbara et al. 
present a new technique for triggering 
oocyte maturation in IVF that has poten-
tial to further reduce the risk of OHSS 
(6). These authors used a kisspeptin, kis-
speptin-54, to stimulate an LH surge, 
which resulted in subsequent egg matura-
tion, fertilization, production of a viable 
embryo, and pregnancy in a small cohort 
of women. Kisspeptins are a group of 
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A 30-year-old primigravid (G1P000) female with infertility secondary to 
her partner’s oligospermia and her chronic anovulation presented 13 days 
after an oocyte retrieval for in vitro fertilization (IVF) with a positive home 
pregnancy test, abdominal distention, a 5-pound weight gain, nausea, 
shortness of breath, and reduced urinary frequency. Her IVF cycle included 
the usual cocktail for gonadotropin stimulation and was uncomplicated, 
except for excessively stimulated ovaries that led to a peak estradiol level of 
6,000 pg/ml and the retrieval of 30 oocytes. Her past history was relevant 
only for anovulation due to polycystic ovarian syndrome (PCOS), though her 
preprocedure body mass index was normal at 21 kg/m2. Pelvic ultrasound 
revealed abundant ascites and enlarged ovaries, at 8 cm average diameter. 
Serum human chorionic gonadotropin (hCG) concentration was 200 mIU/ml; 
she was hemoconcentrated (hemoglobin 16 g/dl), with normal liver function 
and coagulation testing. An ultrasound guided, transvaginal paracentesis 
removed 4 liters of straw-colored fluid, resulting in significant short-term 
symptom relief.
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(10). This report by Jayasena and Abbara 
et al. is likely in the vanguard of a wave 
of new therapeutic options based on an 
increased understanding of the neuro-
peptide control of hypothalamic GnRH 
secretion. Interestingly, emerging data 
also demonstrate that these same neuro-
peptides have direct effects on the ovary 
and endometrium (11, 12), suggesting 
additional applications for these neuro-
peptides and their analogues. Over the 
last 50 years, the field of assisted repro-
duction has benefitted from continued 
innovation, rapidly applying scientific 
advances from the bench to the bedside, 
resulting in steady, significant improve-
ment in the care of the infertile couple 
as well as those with other reproductive 
endocrine disorders. I expect that appli-
cation of newer neuropeptide therapies 
will soon provide yet another significant 
advance in the treatment of reproduc-
tive disorders.
Acknowledgments
This work is supported by grant R01 
HD067721 from the NIH and the Eunice 
Kennedy Shriver National Institute for 
Child Health and Human Development.
Address correspondence to: Steven Young, 
Division of Reproductive Endocrinology 
and Infertility, University of North Caro-
lina, Chapel Hill, North Carolina 27599-
7570, USA. Phone: 919.966.5283; E-mail: 
steven_young@med.unc.edu.
 1. Mansour R, et al. International Committee for 
Monitoring Assisted Reproductive Technologies 
world report: Assisted Reproductive Technology 
peptides produced through differential 
proteolytic processing of the KISS1 gene 
product. The kisspeptins and their G pro-
tein–coupled receptor, GPR54, stimulate 
GnRH secretion by hypothalamic neu-
rons and play a critical physiological role 
in generating the LH surge (7). Therefore, 
functional absence of either receptor or 
ligand results in hypogonadotropic hypo-
gonadism, while activating mutations of 
the receptor can cause precocious puberty 
(8). Furthermore, kisspeptin treatment of 
women with hypogonadotropic hypogo-
nadism can result in resumption of gonad-
otropin secretion (9).
The report by Jayasena and Abbara and 
colleagues builds on previous data and sug-
gests that kisspeptin can be used to gener-
ate an endogenous LH surge in assisted 
reproduction. Jayasena et al. designed a 
pilot dose-finding study that provides pre-
liminary pharmacokinetics. Importantly, 
these preclinical, human data suggest that 
kisspeptin-54 administration results in 
favorable serum LH surge kinetics, efficient 
oocyte maturation, and competence to gen-
erate viable human embryos and babies (6). 
Further testing will be needed to determine 
whether the magnitude and duration of the 
LH surge generated by kisspeptin-54 will be 
consistently optimal for assisted reproduc-
tion and reducing the risk of OHSS.
Conclusions
The use of kisspeptin and other neuro-
peptides and their analogues has the 
potential to replace or augment gonado-
tropins and improve efficacy, safety, and/
or convenience of ovarian stimulation 
